Supplementary Figure 1 from Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status

Authors:
  • IBIdris Bahce
    Idris Bahce
  • ESEgbert F. Smit
    Egbert F. Smit
  • MLMark Lubberink
    Mark Lubberink
  • AVAstrid A. M. van der Veldt
    Astrid A. M. van der Veldt
  • MYMaqsood Yaqub
    Maqsood Yaqub
  • AWAlbert D. Windhorst
    Albert D. Windhorst
  • RSRobert C. Schuit
    Robert C. Schuit
  • ETErik Thunnissen
    Erik Thunnissen
  • DHDaniëlle A. M. Heideman
    Daniëlle A. M. Heideman
  • PPPieter E. Postmus
    Pieter E. Postmus
  • ALAdriaan A. Lammertsma
    Adriaan A. Lammertsma
  • NHN. Harry Hendrikse
    N. Harry Hendrikse

Abstract
PDF file - 43K, Synthesis of 11Cerlotinib. Reaction conditions: 1.0 mg (2.6 μmole) of (1) 6-O-desmethyl-erlotinib, 11CCH3I, 250 μL of acetonitrile, 4.6 μmole of tetra-n-butylammonium hydroxide (2.0 μL of a 60% solution in water), 80 {degree sign}C, 5 min.